Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation
Authors
Keywords
-
Journal
Nature Communications
Volume 10, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-10-17
DOI
10.1038/s41467-019-12628-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Adverse events associated with immune checkpoint inhibitor treatment for cancer
- (2019) Khashayar Esfahani et al. CANADIAN MEDICAL ASSOCIATION JOURNAL
- Metabolic Checkpoints in Differentiation of Helper T Cells in Tissue Inflammation
- (2019) Suyasha Roy et al. Frontiers in Immunology
- Immune checkpoint blockade for organ transplant patients with advanced cancer
- (2019) Pauline De Bruyn et al. CURRENT OPINION IN ONCOLOGY
- Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature
- (2019) Noha Abdel-Wahab et al. Journal for ImmunoTherapy of Cancer
- PI3K/AKT/mTOR pathway inhibitors inhibit the growth of melanoma cells with mTOR H2189Y mutations in vitro
- (2018) Xiaowen Wu et al. CANCER BIOLOGY & THERAPY
- The outcome of checkpoint inhibitor therapy in patients with cancer and solid organ transplant: A systematic review of the literature.
- (2018) Noha Abdelwahab Hassan et al. JOURNAL OF CLINICAL ONCOLOGY
- Complete Tumor Response to Pembrolizumab and Allograft Preservation in Renal Allograft Recipient on Immunosuppressive Therapy
- (2018) Masood Sadaat et al. Journal of Oncology Practice
- Immune Checkpoint Inhibitors and the Risk of Allograft Rejection: A Comprehensive Analysis on an Emerging Issue
- (2018) Luis E. Aguirre et al. ONCOLOGIST
- Immune-related eosinophilia induced by anti-programmed death 1 or death-ligand 1 antibodies
- (2017) Alice Bernard-Tessier et al. EUROPEAN JOURNAL OF CANCER
- Reversal of Autoimmune Toxicity and Loss of Tumor Response by Interleukin-17 Blockade
- (2017) Khashayar Esfahani et al. NEW ENGLAND JOURNAL OF MEDICINE
- Preserved Renal-Allograft Function and the PD-1 Pathway Inhibitor Nivolumab
- (2017) Richard Barnett et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor Regression and Allograft Rejection after Administration of Anti–PD-1
- (2016) Evan J. Lipson et al. NEW ENGLAND JOURNAL OF MEDICINE
- mTOR activation is a biomarker and a central pathway to autoimmune disorders, cancer, obesity, and aging
- (2015) Andras Perl Annals of the New York Academy of Sciences
- mTOR signaling promotes a robust and continuous production of IFN-γ by human memory CD8+T cells and their proliferation
- (2015) Ruka Setoguchi et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Interferon γ (IFNγ) Signaling via Mechanistic Target of Rapamycin Complex 2 (mTORC2) and Regulatory Effects in the Generation of Type II Interferon Biological Responses
- (2015) Barbara Kroczynska et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
- (2015) Dongjun Peng et al. NATURE
- Interferon-γ regulates cellular metabolism and mRNA translation to potentiate macrophage activation
- (2015) Xiaodi Su et al. NATURE IMMUNOLOGY
- Rapamycin inhibition of eosinophil differentiation attenuates allergic airway inflammation in mice
- (2015) Wen Hua et al. RESPIROLOGY
- mTOR signaling, Tregs and immune modulation
- (2014) Nicole M Chapman et al. Immunotherapy
- IL-6 promotes immune responses in human ulcerative colitis and induces a skin-homing phenotype in the dendritic cells and Tcells they stimulate
- (2012) David Bernardo et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- mTOR, metabolism, and the regulation of T-cell differentiation and function
- (2012) Adam T. Waickman et al. IMMUNOLOGICAL REVIEWS
- The mTOR Signalling Pathway in Human Cancer
- (2012) Helena Pópulo et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Allograft rejection is restrained by short-lived TIM-3+PD-1+Foxp3+ Tregs
- (2012) Shipra Gupta et al. JOURNAL OF CLINICAL INVESTIGATION
- Melanoma in Immunosuppressed Patients
- (2012) Agnieszka W. Kubica et al. MAYO CLINIC PROCEEDINGS
- Critical Role of Proinflammatory Cytokine IL-6 in Allograft Rejection and Tolerance
- (2011) X. Zhao et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Single-Cell Analysis of the Human T Regulatory Population Uncovers Functional Heterogeneity and Instability within FOXP3+ Cells
- (2011) E. d'Hennezel et al. JOURNAL OF IMMUNOLOGY
- Metabolism in T cell activation and differentiation
- (2010) Erika L Pearce CURRENT OPINION IN IMMUNOLOGY
- Mammalian Target of Rapamycin Protein Complex 2 Regulates Differentiation of Th1 and Th2 Cell Subsets via Distinct Signaling Pathways
- (2010) Keunwook Lee et al. IMMUNITY
- Skin Inflammation Induced by the Synergistic Action of IL-17A, IL-22, Oncostatin M, IL-1 , and TNF- Recapitulates Some Features of Psoriasis
- (2010) K. Guilloteau et al. JOURNAL OF IMMUNOLOGY
- Rejection of the Kidney Allograft
- (2010) Brian J. Nankivell et al. NEW ENGLAND JOURNAL OF MEDICINE
- The mTOR Kinase Differentially Regulates Effector and Regulatory T Cell Lineage Commitment
- (2009) Greg M. Delgoffe et al. IMMUNITY
- Kidney Transplantation: Mechanisms of Rejection and Acceptance
- (2008) Lynn D. Cornell et al. Annual Review of Pathology-Mechanisms of Disease
- mTOR Is Activated in the Majority of Malignant Melanomas
- (2007) Magdalena Karbowniczek et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now